drugset / Trial / NCT01518244

Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America

NCT01518244

Phase 4 Completed 50 enrolled Alcon Research
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior COMBIGAN® pharmacotherapy in participants with open-angle glaucoma or ocular hypertension.

Timeline

Start
2011-12
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Brinzolamide Small molecule 1 %
Subject Timolol Other / unclassified 0.5 %

Indications